ED50 and ED95 of Remimazolam Combined with Sufentanil for Inhibiting Cardiovascular Responses in Patients with Single-Lumen Endotracheal Intubation
Objective To analyze the median effective dose(ED50)and 95％effective dose(ED95)of remimazolam combined with sufentanil for inhibiting cardiovascular responses in patients with single-lumen endotracheal intubation.Methods A total of 68 patients who underwent single-lumen endotracheal intubation in the First Affiliated Hospital of Henan University from May 2022 to May 2023 were selected as the study subjects.The patients were 20-67 years old,with body mass index of 18-26 kg·m-2 and the American Society of Anesthesiologists(ASA)classification of class Ⅰ-Ⅱ.According to the modified Dixon's sequential test method,the first patient was given intravenous infusion of sufentanil at 0.1 μg·kg-1,and was injected with remimazolam 3 minues later,with an initial dose of 0.2 mg·kg-1.After the patient's got into the loss of consciousness,the patient was treated with 0.6 mg·kg-1 of rocuronium and single-lumen endotracheal intubation.According to the situation of cardiovascular response in the previous patient,the next patient's dose of remimazolam was increased or decreased by a dose gradient of 0.01 mg·kg-1.Probit regression analysis was performed to calculate the ED50 and ED95 of remimazolam combined with sufentanil for inhibiting cardiovascular responses in patients with single-lumen endotracheal intubation.The changes of heart rate(HR),mean arterial pressure(MAP)and oxyhemoglobin saturation(SpO2)at different time points[before anesthesia induction(T,),when the initial bispectral index(BIS)≤60(T2)and after anesthesia induction(T3)]were observed.Results The ED50 and ED95 of remimazolam combined with sufentanil for inhibiting cardiovascular responses in patients with single-lumen endotracheal intubation were 0.180 mg·kg-1(95％CI:0.154-0.196 mg·kg-1)and 0.195 mg·kg-1(95％CI:0.165-0.204 mg.kg-1),respectively.There was no statistically difference in MAP at different time points(P＞0.05).Compared to T1,HR decreased and SpO2 increased at T3 and T4(P＜0.05).After the administration of remimazolam,1 patient suffered from nausea and 1 patient suffered from dizziness,both of them recovered after waking up,without injection pain,hypotension,or bradycardia.Conclusion The ED50 and ED95 of remimazolam combined with sufentanil for inhibiting cardiovascular responses in patients with single-lumen endotracheal intubation are 0.180 mg·kg-1 and 0.195 mg·kg-1,respectively.
万方数据
